Metap1d: A Potential Drug Target and Biomarker (G254042)

Target Name: METAP1D

NCBI ID: G254042

METAP1D

Metap1d: A Potential Drug Target and Biomarker

Introduction

Metap1d is a protein that is expressed in various tissues of the body, including the brain, muscle, and heart. It is a key regulator of cell division and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders . In recent years, researchers have been interested in exploring the potential drug targets and biomarkers for metap1d, with the aim of developing new treatments for a range of diseases. In this article, we will discuss the current understanding of metap1d and its potential as a drug target and biomarker.

Current Understanding of Metap1d

Metap1d is a protein that is composed of multiple domains, including an N-terminal transmembrane domain, a coiled-coil domain, and a C-terminal T-cell receptor-like domain. It is expressed in a variety of tissues and is involved in the regulation of cell division, differentiation, and survival. Metap1d has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of metap1d is its role in cell division. Metap1d is a transcription factor that is involved in the regulation of gene expression and is thought to play a key role in the development and maintenance of cancer. It has been shown to promote the growth and survival of cancer cells and is often used as a potential drug target in cancer treatment.

In addition to its role in cell division, metap1d is also involved in the regulation of cell survival and stress responses. It has been shown to play a key role in the regulation of cell stress and has been implicated in a number of diseases, including neurodegenerative diseases and autoimmune disorders.

Potential Drug Targets for Metap1d

The potential drug targets for metap1d are vast and include a range of diseases and conditions. Some of the most promising targets for metap1d include:

1. Cancer: Metap1d has been shown to promote the growth and survival of cancer cells, making it an attractive target for cancer treatment. Several studies have shown that inhibiting metap1d can lead to the growth inhibition and even the regression of established cancer tumors.
2. Neurodegenerative Diseases: Metap1d has been implicated in the development and progression of a number of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Because it regulates the growth and survival of nerve cells, it may be a promising candidate. drug targets.
3. Autoimmune Disorders: Metap1d has been implicated in the development and maintenance of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. Because it can regulate the growth and survival of immune cells, it may be a potential drug target.

Biomarkers for Metap1d

Metap1d has also been shown to serve as a potential biomarker for a number of diseases. Some of the most promising biomarkers for metap1d include:

1. Blood Pressure: Several studies have shown that metap1d is involved in the regulation of blood pressure and that changes in metap1d levels can affect blood pressure. This suggests that metap1d may be a useful biomarker for the development of hypertension.
2. Heart Rate: Metap1d has also been shown to be involved in the regulation of heart rate and that changes in metap1d levels can affect heart rate. This suggests that metap1d may be a useful biomarker for the development of heart rate disorders.
3. Immune Response: Metap1d has been shown to be involved in the regulation of the immune response and that changes in metap1d levels can affect the immune response. This suggests that metap1d may be a useful biomarker for the development of autoimmune disorders.

Conclusion

In conclusion, metap1d is a protein that is involved in the regulation of cell division, differentiation, and survival. It is a key regulator of cell division and has

Protein Name: Methionyl Aminopeptidase Type 1D, Mitochondrial

Functions: Removes the N-terminal methionine from nascent proteins. The N-terminal methionine is often cleaved when the second residue in the primary sequence is small and uncharged (Met-Ala-, Cys, Gly, Pro, Ser, Thr, or Val). Requires deformylation of the N(alpha)-formylated initiator methionine before it can be hydrolyzed (By similarity). May play a role in colon tumorigenesis

The "METAP1D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about METAP1D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets